ICON appoints chief medical officer
pharmafile | July 4, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | EMA, ICON, buckley
Clinical research organisation ICON has confirmed the appointment of Professor Brendan Buckley as chief medical officer.
Buckley will be ICON’s lead medical expert, representing the company’s position on key scientific, ethical and medical governance matters and will also provide guidance and oversight to the medical and scientific groups across the firm.
An endocrinologist with over 30 years’ experience, Buckley joined ICON through the acquisition of Firecrest Clinical in 2011, where he was one of the founders of the company and senior VP of Medical Affairs.
Buckley is Clinical Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland, and has also been director of the university’s European Center for Clinical Trials in Rare Diseases. He has been a board member of the Irish Medicines Board and of the European Medical Agency (EMA)’s Scientific Advisory Group for Diabetes and Endocrinology since 2005.
He was also a member of the EMA Committee for Orphan Medicinal Products from 2000-2003 and a member of the EMA’s panel of experts. Professor Buckley is also chairman of the Irish Statutory Anti-Doping Agency and is a member of the UK Anti-Doping Scientific Advisory Board.
Ciaran Murray, ICON’s chief executive said: “I would like to congratulate Brendan on his new role and welcome him to ICON’s executive leadership team. Brendan’s wealth of experience both as an advisor to European regulatory agencies and a physician with over 30 years of clinical trial experience, will help us advance our clients’ products through their development pipelines and ensure ICON studies continue to be performed to the highest scientific and ethical standards.”
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera
Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence …
Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis
Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European …
